PMID- 9815549
OWN - NLM
STAT- MEDLINE
DCOM- 19990216
LR  - 20091119
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 3
IP  - 1
DP  - 1997 Jan
TI  - Basic fibroblast growth factor confers growth inhibition and mitogen-activated 
      protein kinase activation in human breast cancer cells.
PG  - 135-42
AB  - The effect of basic fibroblast growth factor (bFGF) on human breast cancer cells 
      was studied in vitro. Exposure to bFGF resulted in significant growth inhibition, 
      decreased DNA synthesis, and accumulation of cells in G0-G1. The IC50 for growth 
      inhibition in MCF-7 cells was 50 pg/ml, and it was abrogated by neutralizing 
      antibodies against bFGF. Inhibition of growth by bFGF was predominant over the 
      growth stimulatory effects of 17beta-estradiol, insulin, or epidermal growth 
      factor. Binding and cross-linking studies of 125I-labeled bFGF in intact MCF-7 
      cells demonstrated 5.2 x 10(3) saturable bFGF binding sites per cell, a 
      dissociation constant of 57 pm, and a Mr 142,000 (125)I-labeled bFGF cross-linked 
      protein. Stimulation of MCF-7 cells with bFGF at concentrations which effected 
      growth inhibition also resulted in activation of p42(mapk) (ERK2) and p44(mapk) 
      (ERK1) mitogen-activated protein kinases. These data demonstrate that whereas 
      bFGF inhibits the growth of several breast cancer cell lines, it concomitantly 
      activates ERK1 and ERK2, generally considered to signal mitogenic rather than 
      growth inhibitory responses. Whether there is association between these phenomena 
      remains unknown.
FAU - Fenig, E
AU  - Fenig E
AD  - Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New 
      York, New York 10021, USA.
FAU - Wieder, R
AU  - Wieder R
FAU - Paglin, S
AU  - Paglin S
FAU - Wang, H
AU  - Wang H
FAU - Persaud, R
AU  - Persaud R
FAU - Haimovitz-Friedman, A
AU  - Haimovitz-Friedman A
FAU - Fuks, Z
AU  - Fuks Z
FAU - Yahalom, J
AU  - Yahalom J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Growth Inhibitors)
RN  - 0 (Iodine Radioisotopes)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 9007-49-2 (DNA)
RN  - EC 2.7.11.17 (Calcium-Calmodulin-Dependent Protein Kinases)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Binding Sites
MH  - Breast Neoplasms/enzymology/*metabolism
MH  - Calcium-Calmodulin-Dependent Protein Kinases/*metabolism
MH  - Cell Cycle/drug effects
MH  - Cell Division/drug effects
MH  - DNA/biosynthesis/drug effects
MH  - Enzyme Activation
MH  - Fibroblast Growth Factor 2/antagonists & inhibitors/*pharmacology
MH  - Growth Inhibitors/pharmacology
MH  - Humans
MH  - Iodine Radioisotopes
MH  - Mitogen-Activated Protein Kinase 1
MH  - Mitogen-Activated Protein Kinase 3
MH  - *Mitogen-Activated Protein Kinases
MH  - Tumor Cells, Cultured
EDAT- 1997/01/01 00:00
MHDA- 1998/11/17 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1998/11/17 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - Clin Cancer Res. 1997 Jan;3(1):135-42.